The MIRACLE programme brings together leading academic and biotech industrial partners to train the next generation of innovation-minded researchers who can advance precision medicine approaches for cardiometabolic diseases (CMD).
CMD are among the most common and burdensome health conditions worldwide. This group of conditions includes cardiovascular and metabolic disorders such as atherosclerosis, type 2 diabetes, and non‑alcoholic steatohepatitis. These highly prevalent diseases are closely associated with metabolic imbalances, including obesity and insulin resistance, and are characterised by chronic, low-grade inflammation that gradually damages tissues and contributes to disease progression. Despite their high prevalence and impact on healthcare systems, the biological mechanisms driving inflammation in CMD remain incompletely understood.
Current anti-inflammatory therapies used to manage cardiometabolic conditions often act broadly on the immune system. However, these therapies frequently lack specificity and do not fully address the diverse mechanisms underlying CMD. This highlights the need for more precise therapeutic strategies that target the specific pathways responsible for disease-related inflammation.
The MIRACLE programme aims to expand current knowledge of the mechanisms that regulate inflammation in CMD and to support the development of more targeted therapeutic strategies. The project combines expertise from academic research and biotechnology sectors and integrates cutting-edge technologies to investigate how local tissue environments, cellular interactions and molecular signals contribute to chronic inflammation in CMD.
To achieve these goals, the programme follows a multidisciplinary research strategy. First, advanced single-cell technologies are applied to characterise diseased tissues at multiple biological levels. Second, the project examines how local environmental signals shape cellular communities and influence interactions between immune and non-immune cells. Third, multiple layers of biological data are integrated to identify regulatory networks that control inflammatory processes. Finally, the knowledge generated is used to support the evaluation of potential therapeutic strategies in advanced experimental models.
Beyond its scientific objectives, MIRACLE is designed as a comprehensive doctoral training programme that integrates academic and non-academic sectors. It equips Doctoral Candidates with advanced interdisciplinary expertise spanning molecular biology, computational analysis, translational research, and innovation management. This integrated approach strengthens Europe’s capacity to generate highly skilled researchers capable of bridging fundamental discovery and therapeutic development.
